First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets turns positive
Q1 FY2026 other current assets was $2.95M, compared with -$385.37M a year earlier.
Context
- Other current assets amounted to 1.0% of total assets at the end of Q1 FY2026.
- Other current assets increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +100.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Other Current Assets vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 other current assets of $2.95M is the 7th highest of the 10 companies compared; the peer median is $3.46M.
- Its year-over-year change of +100.8% is the 2nd highest of 8, against a peer median of -26.2%.
- Other current assets amounts to 1.0% of total assets for TRAX, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $37.63M | -24.3% | — | 4.9% | |
| Mar 2026 | $32.96M | — | — | 8.2% | |
| Mar 2026 | $3.91M | -26.2% | +1.6% | 1.2% | |
CLYMClimb Bio, Inc. | Mar 2026 | $3.84M | +3268.4% | +16.6% | 2.5% |
| Jun 2026 | $3.46M | -3.7% | — | 1.5% | |
| Jun 2026 | $3.27M | — | — | 2.5% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $2.95M | +100.8% | — | 1.0% |
| Mar 2026 | $1.06M | -54.7% | -30.6% | 0.6% | |
| Mar 2026 | $9K | -83.6% | -26.8% | 0.0% | |
| Mar 2026 | $0 | -100.0% | +59.8% | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $3.46M | -26.2% | +1.6% | 1.5% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.